Search hospitals > New Mexico > Albuquerque

University of New Mexico Health Sciences Center

Claim this profile
Albuquerque, New Mexico 87102
Global Leader in Coronavirus
Global Leader in High Blood Pressure
Conducts research for Pulmonary Arterial Hypertension
Conducts research for COVID-19
Conducts research for Infections
94 reported clinical trials
10 medical researchers
Photo of University of New Mexico Health Sciences Center in AlbuquerquePhoto of University of New Mexico Health Sciences Center in AlbuquerquePhoto of University of New Mexico Health Sciences Center in Albuquerque

Summary

University of New Mexico Health Sciences Center is a medical facility located in Albuquerque, New Mexico. This center is recognized for care of Coronavirus, High Blood Pressure, Pulmonary Arterial Hypertension, COVID-19, Infections and other specialties. University of New Mexico Health Sciences Center is involved with conducting 94 clinical trials across 218 conditions. There are 10 research doctors associated with this hospital, such as Davin Quinn, MD, Andrew Carlson, MD, Michel Torbey, MD, and Joao P Teixeira, MD.

Area of expertise

1Coronavirus
Global Leader
University of New Mexico Health Sciences Center has run 14 trials for Coronavirus. Some of their research focus areas include:
SARS-CoV-2
SARSCo2
RT-PCR
2High Blood Pressure
Global Leader
University of New Mexico Health Sciences Center has run 12 trials for High Blood Pressure.

Top PIs

Clinical Trials running at University of New Mexico Health Sciences Center

Pulmonary Arterial Hypertension
High Blood Pressure
Pulmonary Hypertension
Spinal Cord Injury
Coronavirus
Brain Arteriovenous Malformation
Heart Failure
Septic Shock
Opioid Overdose
Spinal Fracture
Image of trial facility.

Sotatercept

for Pulmonary Arterial Hypertension

This trial is testing sotatercept, a medication for high blood pressure in the lungs, in adults with PAH who have completed earlier studies. It aims to see if the medication is safe and effective over a long period. Sotatercept helps lung blood vessels function better, reducing lung pressure. Sotatercept has shown promising results in earlier studies for reducing lung pressure and improving exercise tolerance in patients with pulmonary arterial hypertension (PAH).
Recruiting2 awards Phase 39 criteria
Image of trial facility.

Seralutinib

for Pulmonary Arterial Hypertension

This trial is testing a medication called seralutinib to see if it can help people with a specific type of lung disease (PAH) improve their ability to exercise. The medication works by blocking signals that cause the blood vessels in the lungs to tighten and narrow. Seralutinib is delivered via inhalation and is being developed for patients with pulmonary arterial hypertension. The goal is to see if this can reduce lung pressure and delay worsening of the disease.
Recruiting1 award Phase 313 criteria
Image of trial facility.

Sotatercept

for Pulmonary Arterial Hypertension

This trial is testing sotatercept, a new medication, to see if it can help people with a specific type of high blood pressure in the lungs (PAH) when added to their usual treatment. The study focuses on patients who are newly diagnosed and at higher risk of their condition worsening. Sotatercept aims to reduce the pressure in the lung's blood vessels, potentially slowing down disease progression. Sotatercept has shown significant reduction in pulmonary vascular resistance and maintained clinical efficacy in previous studies.
Recruiting1 award Phase 310 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of New Mexico Health Sciences Center?
University of New Mexico Health Sciences Center is a medical facility located in Albuquerque, New Mexico. This center is recognized for care of Coronavirus, High Blood Pressure, Pulmonary Arterial Hypertension, COVID-19, Infections and other specialties. University of New Mexico Health Sciences Center is involved with conducting 94 clinical trials across 218 conditions. There are 10 research doctors associated with this hospital, such as Davin Quinn, MD, Andrew Carlson, MD, Michel Torbey, MD, and Joao P Teixeira, MD.